So, just how much are those CRISPR patents actually worth?
There was a single question conspicuously absent in all the discussion over last week’s CRISPR patent ruling (a single number, really): How much are the patents actually worth?
The US Patent and Trademark Office ruling, after years of legal wrangling, that Feng Zhang and The Broad Institute — not Jennifer Doudna, Emmanuelle Charpentier and the UC Berkeley group — deserve credit for inventing CRISPR/Cas9 gene editing in human cells will assuredly mean a windfall for the academic center and any companies with which it’s associated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.